Patrys starts manufacturing and regulatory work for RLS-2201 trial
Patrys Ltd (ASX:PAB) has begun manufacturing and regulatory activities for RLS-2201, its proprietary injectable quetiapine formulation being developed to treat delirium, as it works toward launching a first-in-human Phase 0 clinical trial in the second …